Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase II Avastin Trial for Stage IIIB/IV NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00766246
Recruitment Status : Terminated (Withdrawal of funding support)
First Posted : October 3, 2008
Last Update Posted : April 19, 2016
Genentech, Inc.
Information provided by (Responsible Party):

Brief Summary:
This is a randomized, open-label, multicenter study in 160 patients in first line treatment and 114 in second line treatment with advanced or metastatic NSCLC (Stage IIIB/IV).

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Stage IV Drug: bevacizumab Drug: docetaxel Drug: carboplatin Phase 2

Detailed Description:
This phase II clinical trial will address the issues of bevacizumab treatment duration and treatment safety as first-line therapy for patients with non-squamous NSCLC. Following disease progression or treatment failure, the potential benefit of continued bevacizumab therapy will be tested by randomizing patients to two treatment arms, including second-line chemotherapy with or without further bevacizumab. It is hypothesized that continuation of bevacizumab with pemetrexed as second-line treatment following progression will result in improved clinical outcomes for patients with NSCLC.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 125 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Study Start Date : October 2008
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: First-line
Carboplatin, docetaxel, bevacizumab Open-label, single arm with treatment period up to 6 cycles. Patients completing a total of 2 to 6 cycles of first-line without disease progression will be eligible for maintenance.
Drug: bevacizumab
15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
Other Name: Avastin

Drug: docetaxel
75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
Other Name: Taxotere

Drug: carboplatin
AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
Other Name: Paraplatin

Experimental: Maintenance
Bevacizumab Open-label, single arm with treatment period up to 18 cycles.
Drug: bevacizumab
15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
Other Name: Avastin

Primary Outcome Measures :
  1. Progression-free survival (PFS) of bevacizumab and pemetrexed compared to pemetrexed monotherapy during second-line treatment of Stage IIIB or IV NSCLC [ Time Frame: Duration of study ]

Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Duration of the study ]
  2. Objective tumor response (objective response rate [ORR]) in second-line treatment [ Time Frame: Duration of the study ]
  3. Progression-free survival (PFS) in first-line and maintenance treatment [ Time Frame: Duration of the study ]
  4. Objective tumor response (objective response rate [ORR]) in first-line and maintenance treatment [ Time Frame: Duration of the study ]
  5. Treatment safety in first-line, maintenance and second-line treatment [ Time Frame: Duration of the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 years
  • Histologically or cytologically confirmed stage IIIB with malignant pleural effusion or stage IV NSCLC except squamous-cell carcinoma
  • Measurable disease defined by RECIST
  • Adequate organ function:

    1. Absolute neutrophil count ≥ 1.5 x 10(9)/L
    2. Hemoglobin ≥ 9.0 g/dL
    3. Platelets ≥ 100 x 10(9)/L
    4. Hepatic enzyme levels: AST and ALT and Alkaline Phosphatase must be within range allowing for eligibility. In determining eligibility, the more abnormal of the two values (AST or ALT) should be used according to table listed in the protocol
    5. Bilirubin ≤ ULN
    6. Serum Creatinine ≤ 1.5 mg/dL (or creatinine clearance ≥ 60mL/min)
    7. Urine protein/creatinine ratio < 1.0 OR urine dipstick for proteinuria < 2 + (patients discovered to have ≥ 2 + proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤1g of protein in 24 hours to be eligible)
    8. INR ≤ 1.5
    9. PTT ≤ ULN
  • ECOG Performance Status 0-1
  • Estimated survival of ≥ 12 weeks
  • Provide written informed consent

Exclusion Criteria:

  • Prior chemotherapy for advanced NSCLC
  • Neoadjuvant or adjuvant treatment within six (6) months of registration
  • Prior radiation therapy within three (3) weeks of registration; all side effects must have resolved by registration
  • Prior treatment with an investigational or marketed agent that acts by antiangiogenesis mechanisms
  • Large ( > 4 cm) centrally located lesions or large lesions in close proximity to major blood vessels unless treated with palliative radiation
  • Brain metastases or leptomeningeal disease, except for patients who have had a resection and/or completed a course of cranial irradiation, have no worsening CNS symptoms, and have discontinued all corticosteroids for that indication for at least one (1) month prior to registration
  • History of gross hemoptysis (defined as bright red blood of at least ½ teaspoon or 2.5 mL per episode) within three (3) months of registration unless definitively treated with surgery, radiation, arteriographic embolization, or endobronchial interventions at least four (4) weeks prior to registration
  • Presence of cavitory lesion
  • Presence of squamous histology (mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible; sputum cytology alone is not acceptable)
  • Peripheral neuropathy > grade 1
  • Major surgery, open biopsy or significant traumatic injury within four (4) weeks of registration or anticipation of need for major surgical procedure during the course of the study
  • Minor surgical procedures, fine needle aspirations or core biopsies within one (1) week prior to registration
  • Current, ongoing therapeutic anticoagulation with full-dose warfarin or its equivalent
  • Current or recent (within ten [10] days of the first dose of study treatment) use of aspirin (at least 325 mg/day) or other NSAIDs with anti-platelet activity or treatment with dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix), or cilostazol (Pletal)
  • History of prior malignancy within the past three (3) years except for curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or treated localized prostate cancer with a current PSA of < 1.0 mg/dL on two successive evaluations, at least three (3) months apart, with the most recent evaluation no more than four (4) weeks prior to registration
  • History of serious systemic disease including:

    1. Unstable angina, New York Heart Association (NYHA) ≥ Grade II or congestive heart failure
    2. Inadequately controlled hypertension (blood pressure >150/100 mmHg while taking antihypertensive medications)
    3. Unstable symptomatic arrhythmia requiring medication
    4. Myocardial infarction within six (6) months prior to registration
    5. Stroke within six (6) months prior to registration
    6. Transient ischemic attack within six (6) months prior to registration
    7. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within six (6) months prior to registration
    8. Clinically significant peripheral vascular disease or evidence of bleeding, diathesis (prone to bleeding) or coagulopathy
    9. Active systemic bacterial, fungal or viral infection, including known HCV and HIV
  • Pregnancy or women who are breast-feeding; women of child-bearing potential and non-vasectomized men must agree to use effective methods of birth control during and three (3) months following treatment period and women of child-bearing potential must have a negative pregnancy test
  • History of severe hypersensitivity reaction to docetaxel or any other drugs formulated with polysorbate 80
  • Any other medical condition, including mental illness or substance abuse, which in the judgment of the investigator, is likely to interfere with a patient's ability to provide informed consent, cooperate, and participate in the study, or to interfere with the interpretation of the results
  • Use of any investigational agent within four (4) weeks prior to registration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00766246

Sponsors and Collaborators
Genentech, Inc.
Layout table for investigator information
Principal Investigator: Chandra P Belani, MD Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Penn State Hershey Cancer Institute
Layout table for additonal information
Responsible Party: Pharmatech Identifier: NCT00766246    
Obsolete Identifiers: NCT00735891
Other Study ID Numbers: PSHCI 08-009
First Posted: October 3, 2008    Key Record Dates
Last Update Posted: April 19, 2016
Last Verified: April 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Keywords provided by Pharmatech:
Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Lung Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action